01—Abstract
Summary
Summary of the 8-K filed August 17, 2026. Cited figures are marked; the original filing is the authoritative source.
MetLife, Inc. (NYSE: MET) announced on August 17, 2026 that it has declared its third quarter 2026 preferred stock dividends across four series, as disclosed under Item 8.01 of this Form 8-K with the news release attached as Exhibit 99.1.
The declarations cover the floating rate non-cumulative Series A (quarterly, $0.31471411a per share), the 5.875% fixed-to-floating Series D (semi-annual, $29.375 per share on $1,000 liquidation preference), the 5.625% Series E (quarterly, $0.3515625 per depositary share), and the 4.75% Series F (quarterly, $0.296875 per depositary share). All dividends are payable September 15, 2026, to holders of record as of August 31, 2026. This is a routine capital-management disclosure rather than a material operational or financial event.
The filing contains no earnings data, guidance changes, balance sheet updates, or new capital actions such as issuances or repurchases. The dividends are non-cumulative, meaning MetLife has no obligation to pay missed amounts, so each declaration is a discretionary board decision that signals ongoing confidence in the company's capital position.
For investors, the main takeaway is that MetLife continues to service its preferred capital stack on schedule, which supports the credit profile of these instruments and reflects the company's ongoing use of hybrid capital. Investors in the preferred securities should note the payment dates and record dates, while common shareholders will find little new information here beyond confirmation of the ongoing preferred capital structure.
02—Key points
Key Highlights
- MetLife declared third quarter 2026 dividends on four preferred stock series: Series A, Series D, Series E, and Series F.
- Series A (NYSE: MET PRA), a floating rate non-cumulative preferred with $25 liquidation preference, will pay a quarterly dividend of $0.31471411 per share.
- Series D, a 5.875% fixed-to-floating rate non-cumulative preferred with $1,000 liquidation preference, will pay a semi-annual dividend of $29.375 per share.
- Series E (NYSE: MET PRE), a 5.625% non-cumulative preferred, will pay $0.3515625 per depositary share quarterly, with each depositary share representing 1/1,000th of a preferred share.
- Series F (NYSE: MET PRF), a 4.75% non-cumulative preferred, will pay $0.296875 per depositary share quarterly, with each depositary share representing 1/1,000th of a preferred share.
- All dividends are payable September 15, 2026, to shareholders of record as of August 31, 2026.
- The filing contains no financial results, guidance, or new capital transactions; it is a routine preferred dividend declaration.
03—Questions
Frequently Asked Questions
When will the preferred dividends be paid and who receives them?
The dividends are payable on September 15, 2026, to holders of record as of the close of business on August 31, 2026.
Are these preferred dividends guaranteed?
No. The preferred stock is non-cumulative, so each dividend is declared at the board's discretion and missed payments do not accumulate or become owed later.
What is the difference between the depositary shares and the underlying preferred shares for Series E and F?
Series E and F are offered as depositary shares, each representing a 1/1,000th interest in a share of the underlying preferred stock. Investors holding depositary shares receive the per-depositary-share amount ($0.3515625 for Series E and $0.296875 for Series F), not the full per-share figure.
Does this filing affect MetLife's earnings or financial outlook?
No. The 8-K only announces routine preferred dividend declarations and does not include financial results, guidance changes, or updates to the balance sheet.
Why is the Series A dividend expressed with eight decimal places?
Series A is a floating rate preferred, so its quarterly dividend is calculated from a reference rate plus a spread and resets each period. The resulting per-share amount is therefore an unrounded figure set by that formula.
04—Continue